The clinical efficacy of Rev-Eyes in reversing the effects of pupillary dilation.

BACKGROUND

Pupillary dilation to perform binocular indirect ophthalmoscopy has become a routine part of optometric practice. Many patients find the resulting photophobia and incapacity of near vision to be an inconvenience. Rev-Eyes (0.5% dapiprazole HCl) is a new alpha-antagonist reported to reverse the effects of pupillary dilation in approximately one hour. This study was designed to evaluate the usefulness of Rev-Eyes in a routine clinical setting.

METHODS

Seventy-nine subjects free of eye disease that ranged in age from 21 to 40 years received 0.5% proparacaine, 2.5% phenylephrine, and 1.0% tropicamide in each eye. Rev-Eyes was administered to 61 subjects. Eighteen control subjects received 5% NaCl. Effects on pupil diameter, accommodation, and distance and near visual acuity were measured. Conjunctival vasodilation, corneal stippling, patient comfort, and intraocular pressure (IOP) were also evaluated.

RESULTS

Our results confirm that a statistically significant reduction in pupil diameter is achieved 60 minutes after installation of Rev-Eyes. However, no significant improvement was obtained in any of the other functional aspects measured

CONCLUSIONS

Our data suggest limited utility for Rev-Eyes with a young population. The recovery rate of near visual acuity and amplitude of accommodation is identical with or without Rev-Eyes.